Abstract
Immunoglobulin E (IgE)-mediated food allergy impacts 8% of US children,1 with peanut allergy prevalence steadily increasing.2 Food allergy affects everyday activities for food-allergic children and their parents,3 which can increase anxiety and reduce health-related quality of life (QoL).4,5 Although several peanut-desensitization methods are being studied, no approved treatments exist for peanut-allergic patients.6,7 Current research is mainly focused on efficacy and safety; however, considering participant quality of life (QoL) after peanut-immunotherapy clinical trials is important.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
